MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

Date of Original Release: December 14, 2017
Date CME Credit No Longer Available: December 14, 2019

Learning Objectives

At the conclusion of this course, participants should be able to: 

• Discuss disease-modifying therapies in clinical trials for Parkinson's disease, including repurposed drugs and novel therapies targeting genetic mutations. 
• Summarize progress in Parkinson's symptomatic therapies, including recently approved drugs and therapies in clinical trials to treat motor and non-motor symptoms. 
• Identify advances in disease understandings and describe how these are leading toward new treatment approaches and more efficient trials.

Target Audience

This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.

Faculty

Andrew Siderowf, MD
Director, Parkinson Disease Movement Disorder Center
University of Pennsylvania
Disclosures: Advisory Role, Voyager; Former Employee, Eli Lilly and Co.; Independent Contractor, Biogen and Wave

Todd Sherer, PhD
Chief Executive Officer 
The Michael J. Fox Foundation
Wife employed at Pfizer

Dave Iverson
Moderator
Nothing to disclose

Douglas DuMond
Person with Parkinson's
Nothing to disclose